Table 1 COX univariate and multivariate analysis for the effect of ZAK expression on overall survival
From: Mixed lineage kinase ZAK promotes epithelial–mesenchymal transition in cancer progression
Clinicopathological parameters | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | |
Biomarkers | ||||
ZAK (+) | 2.726 (1.368–5.435) | 0.004 | 2.775 (1.344–5.730) | 0.006 |
ER (+) | 0.455 (0.244–0.846) | 0.013 | 0.843 (0.313–2.275) | 0.737 |
PR (+) | 0.507 (0.272–0.946) | 0.033 | 0.647 (0.317–1.324) | 0.233 |
HER2 (+) | 1.023 (0.529–1.977) | 0.947 | 0.648 (0.322–1.305) | 0.224 |
Lymph node status | ||||
pN2–3 (vs. pN0–1) | 2.391 (1.323–4.322) | 0.004 | 2.458 (1.298–4.656) | 0.006 |
Combination 1 | ||||
ZAK + ER− (vs. ZAK-ER + ) | 3.779 (1.614–8.849) | 0.002 | 3.417 (1.458–8.010) | 0.005 |
Combination 2 | ||||
ZAK + PR− (vs. ZAK-PR + ) | 3.288 (1.426–7.585) | 0.005 | 3.654 (1.514–8.821) | 0.004 |
Combination 3 | ||||
ZAK + HER2− (vs. ZAK-HER2−) | 3.401 (1.485–7.786) | 0.004 | 3.637 (1.518–8.717) | 0.004 |
Combination 4 | ||||
ZAK + Basal like (vs. ZAK-Luminal type) | 4.509 (1.825–11.144) | 0.001 | 4.357 (1.759–10.791) | 0.001 |
Combination 5 | ||||
ZAK + pN2–3 (vs. ZAK-pN0–1) | 6.538 (2.548–16.774) | <0.001 | 5.831 (2.234–15.224) | <0.001 |
